Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 669 results

Media Release / Dec 13, 2011

Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia

- Trial shows Exjade, an iron chelator, is significantly better than placebo at reducing liver iron concentration in patients with NTDT- Non-transfusion-dependent thalassemia (NTDT) is a genetic…
Media Release / Dec 13, 2011

Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
Media Release / Dec 12, 2011

Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®

- ENESTcmr data show 23% of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11% who continued on Gleevec(1)- Three-year ENESTnd data show 32% of…
Media Release / Dec 12, 2011

Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Media Release / Nov 07, 2011

Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis

- Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty[2],[3]- The new pivotal Phase III data also showed…
Media Release / Nov 07, 2011

Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Media Release / Sep 26, 2011

Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing

-- Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone(1)-- Study shows everolimus significantly…
Media Release / Sep 25, 2011

Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
Media Release / Sep 25, 2011

Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

- Phase III IMPRES study demonstrates potential benefits of QTI571 in patients who remain symptomatic despite treatment with two or more PAH therapies(1)- Evidence indicates that QTI571 targets an…
Media Release / Sep 25, 2011

Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

‹ Previous page
1
…
56
57
58
59
60
61
62
…
67
› Next page